FOUNTAIN HILLS, Ariz., Sept 28, 2010 /PRNewswire via COMTEX/ -- Sunridge International (OTC Bulletin Board: SNDZ) said today that their treatment for glaucoma and ocular hypertension will be introduced in October to eye doctors and the medical community in India.
Presentations have been planned by its Indian distributors, New Amsterdam Marketing Corporation, in major cities from October 1 - 14. The company's Pneumatic Trabeculoplasty (PNT), treatment is a cost-effective, non-invasive procedure designed to reduce pressure on the retinal nerve. The two-minute procedure, easily performed in a clinic or doctors office, is required only three or four times a year. It is a treatment regime that is especially valuable to patients in rural areas, where traditional medical facilities are limited.
Sunridge International, the developer and marketer of the PNT treatment, announced today that it's exclusive marketer in India, will be holding meetings to demonstrate the procedure to hundreds of medical personnel throughout the country.
The first presentations will be held at the (www.apos.in) conference in Hyderabad from October 1-3. This will be followed by meetings in Calcutta, Mumbai and Jaipur. The presentations will be led by Dr. Leo Bores, M.D. Dr. Bores also will be holding private meetings over a two week period in India.
G. Richard Smith, CEO of Sunridge International, said the company was especially pleased to be able to bring the PNT procedure to India. "We are introducing our PNT equipment and treatments in many markets throughout the world, including the European Union countries, China and Latin America. But India is a very special place. It offers enormous opportunity for us."
"Working with New Amsterdam colleagues, we look forward to helping, perhaps, thousands of people suffering from glaucoma and ocular hypertension throughout the country. Often in the rural countryside, with a very poor population, glaucoma is left untreated. For many the cost of ongoing treatment is simply out of their reach. We strongly believe that PNT provides an answer to this problem, and gives people an opportunity for a safe, effective and affordable treatment.
"We will be giving the doctors and medical personnel attending the New Amsterdam presentations our fullest support and look forward to a long and mutually rewarding association with them."
Glaucoma is the second leading cause of blindness, affecting more than 70 million people worldwide. Studies completed over the last 10 years have proven that PNT is a safe effective and cost effective alternative treatment for glaucoma and ocular hypertension. The two-minute treatment has been developed, patented and distributed by Sunridge International's wholly-owned subsidiary, Ophthalmic International.(www.oi-pnt.com).
